Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Abstract

[This corrects the article on p. 1921 in vol. 12, PMID: 30323548.].

Figure 3

The LS mean CFB in total conjunctival lissamine green staining scores by study visit is presented for the vehicle group (open squares), OTX-101 0.05% group (light blue diamonds) and OTX-101 0.09% group (dark blue circles). Notes: Statistically significant reductions in the LS mean CFB relative to vehicle were observed for OTX-101 0.09% at Day 84 (P=0.0076), and for the OTX-101 0.05% group at Day 56 (P=0.029) and Day 84 (P=0.006). Abbreviations: CFB, change from baseline; LS, least squares; SE, standard error.